Ten patients with advanced Hodgkin's disease refractory to combination therapy with nitrogen mustard, vincristine sulfate, procarbazine, and prednisone (MOPP) were treated with a combination of doxorubicin hydrochloride and lomustine. Toxicity was acceptable. Five patients (50%) attained complete remission (median duration, 15 months). Three patients attained a partial remission (median duration, four months). Survival ranged from three to more than 40 months, and five patients are still alive. One patient remains disease-free after a course of radiation therapy to a site of localized nodal relapse. The doxorubicin-lomustine regimen has induced meaningful remissions in a patient population with very refractory disease.
(JAMA 238:1659-1661, 1977)
Williams SD, Einhorn LH. Combination Chemotherapy With Doxorubicin and Lomustine: Treatment of Refractory Hodgkin's Disease. JAMA. 1977;238(15):1659–1661. doi:10.1001/jama.1977.03280160053028
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: